Longeveron Inc (LGVN)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$6.81+3.50%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · LGVN
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 653.0% |
| Our one-year growth estimate | diamond | -43.9% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 696.9 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
LGVN — litigation filed
Dated 2026-08-24
and shall not be deemed “filed” for the purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Exchange Act of 1934, as amended, or the Securities Act of 1933, as amended, except as shall be expressly set forth by reference in such a filing. Cautionary Note Regarding Forward-Looking Statements This Current Report on Form 8-K and certain of the materials filed herew…
Why it matters: If healthcare sector revenue growth speeds up, it may benefit Longeveron Inc. and improve its outlook.
Supportive ifHealthcare sector revenue growth returns to near 10% year over year.
Worry ifHealthcare sector revenue growth continues to slow below current levels.
Why it matters: The FDA's view on trial endpoints will impact the path to potential approval. Clear guidance could boost confidence.
Supportive ifFDA agrees to a new primary endpoint that supports efficacy in the ELPIS II trial.
Worry ifThe FDA says the main goal is not enough to show effectiveness.
Why it matters: Good cash management helps a company survive when it loses money.
Worry ifA report shows positive cash flow from operations.
Less concerning ifNegative cash flow from operations is over -$4.37M.
Why it matters: Updates on cash and financing plans show if the company can fund its work.
Worry ifA new financing or partnership is announced. This will help extend cash runway.
Less concerning ifThere is news of cash running low or failure to get more financing.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$241 on $10,000 · ±2.4% | How much price usually moves either way. |
| Bad day | $690 loss on $10,000 · 6.9% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,871 loss on $10,000 · 48.7% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Results from this trial are key to Longeveron's future. Positive results could boost investor confidence in the therapy.
Supportive ifThe Phase 2b laromestrocel trial shows a clear improvement in results.
Worry ifResults show no clear improvement or do not meet main goals.
Why it matters: Compliance with Nasdaq rules is critical for Longeveron's listing. Failure to comply could lead to delisting.
Worry ifThe company solved its problems with Nasdaq compliance.
Less concerning ifFurther notices of non-compliance or failure to meet listing standards.
Why it matters: These results are crucial for the future of laromestrocel in treating HLHS. Positive results could lead to FDA filing and partnerships.
Supportive ifThe ELPIS II trial shows better heart function results.
Worry ifThe ELPIS II trial shows no change in heart function.
Why it matters: The new CFO's leadership can change financial plans and affect investor trust. A smooth change is important for stability.
Watch forMarie Washburn is the new CFO. She has a clear plan for finances.
Also watch forThe change is delayed or causes confusion in financial reports.
Why it matters: Compliance with Nasdaq rules is crucial for maintaining the company's listing. Non-compliance could lead to delisting.
Worry ifThe company confirms it meets Nasdaq's minimum bid price and audit rules.
Less concerning ifNasdaq sent more warnings about breaking listing rules.
Why it matters: The results will show if laromestrocel is effective for treating HLHS. This could impact future funding and partnerships.
Supportive ifThe ELPIS II trial shows laromestrocel helps HLHS patients.
Worry ifResults show laromestrocel does not work or has safety issues.
Why it matters: Updates on cash and financing plans will show if the company can keep going.
Worry ifManagement says cash reserves will last until Q4 2026 without more funding.
Less concerning ifManagement says cash will run out before Q4 2026 or plans for big dilution.
Why it matters: The reverse split aims to regain compliance with Nasdaq. Its success may affect stock price and investor interest.
Watch forStock price stabilizes above $1.00 after the reverse split.
Also watch forStock price remains below $1.00 or continues to decline post-split.